Analysis of Safety and Efficacy of Intragastric Balloon in Extremely Obese Patients

GÖttig, Stephan; Daskalakis, Markos; Weiner, Sylvia; Weiner, Rudolf A.

doi:10.1007/s11695-009-9820-z

Cited by 55 publications

(37 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of those in the IGBG experienced GIrelated AEs. These were mainly reported during the initial adaptation phase (days [1][2][3][4][5][6][7][8][9][10][11][12][13][14] and mostly resolved during the second week post-insertion ( Figure 4). Consistent with this, when an analysis was conducted of the impact of the three most common symptoms (nausea, vomiting, and abdominal pain) on daily functioning (defined as: days off work or study), the mean (SD) number of days impacted during week 1 was: 3.7 (0.9), reducing to 0.6 (1.4) days during week 2.…”

Section: Safetymentioning

confidence: 99%

See 1 more Smart Citation

An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

Fuller

Pearson

Lau

et al. 2013

Obesity

View full text Add to dashboard Cite

Objective: There are limited controlled data for intragastric balloons (IGB) in obesity treatment. This randomized, controlled study evaluated the efficacy and safety of an IGB in obese individuals with metabolic syndrome (MS). Design and Methods: Sixty-six adults (BMI: 30-40 kg/m 2 ) were randomized to IGB for 6 months, with a 12 month behavioral modification (IGB Group; ''IGBG''), or 12 month behavioral modification alone (Control Group; ''CG''). The primary outcome was percentage change in body weight. Results: Thirty-one subjects (female: 68%; mean age: 43; mean BMI: 36.0) were randomized to IGBG and 35 (66%; 48; 36.7) to CG. At 6 months, there was a significantly greater weight loss in the IGBG: À14.2 vs. À4.8; P < 0.0001. This was associated with a significantly greater reduction in waist circumference, and an improvement in quality of life, with a trend for a larger %MS remission (50% vs. 30%; n.s.). At month 12, the differences in weight loss were enduring: À9.2 vs. À5.2; P ¼ 0.007. Gastrointestinal-related adverse events were common in the IGBG, resolving predominantly within two weeks. The IGB was removed prematurely in three subjects (one for refractory gastrointestinal symptoms). Conclusions: Statistically significant and clinically relevant improvements in weight loss and health outcomes were observed with the IGBG at 6 months versus behavioral modification alone. The differential weight loss was still evident 6 months after IGB removal.

show abstract

Section: Safetymentioning

confidence: 99%

“…The majority of these studies have been uncontrolled and/or retrospective (13)(14)(15)(16)(17)(18)(19)(20). Only three studies published to date employed a prospective, randomized, controlled trial design with a long-term follow-up (!1 year) (21-23); two of which included the use of more than one IGB (21,22).…”

Section: Introductionmentioning

confidence: 99%

An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

Fuller

Pearson

Lau

et al. 2013

Obesity

View full text Add to dashboard Cite

show abstract

“…IGB placement is performed in patients who cannot lose enough weight with conservative treatment, who are not candidates for surgery or who do not wish to have surgical intervention [13]. In this procedure, balloons of different size and stability are used and can be inflated with air or liquid [11]; in our clinic, adjustable balloons that can be remained in the stomach for up to 12 months are used and inflated with saline.…”

Section: Discussionmentioning

confidence: 99%

Laparoscopic sleeve gastrectomy versus endoscopical intra-gastric balloon placement: early results of morbidly obese patients

Çaycı

Erdoğdu

2017

Archives of Clinical and Experimental Medicine

View full text Add to dashboard Cite

Atıf yazım şekli:How to cite:Cayci HM, Erdogdu U. Laparoscopic sleeve gastrectomy versus endoscopic intra-gastric balloon placement: Early results of morbidly obese patients. Arch Clin Exp Med. 2017;2(2):35-38.Abstract Aim: Endoscopic intra-gastric balloon (IGB) placement and laparoscopic sleeve gastrectomy (LSG) are widely used treatment modalities for weight loss in patients with morbid obesity. The aim of our study was to evaluate the results of these two methods in patients with morbid obesity. Methods: The data of 119 patients who were treated during the same time period for morbid obesity (Body Mass Index (BMI) ≥40 kg/m2) and completed a 12-month follow-up period were evaluated retrospectively. The study comprised twenty patients who underwent IGB placement and 99 LSG patients. Patients from these two groups were compared according to their demographic data; rate of comorbidity; weight and BMI changes both preoperatively and postoperatively at the 12 months; excess weight loss (EWL); and excess BMI loss (EBL ) nedeniyle aynı dönemde tedavi edilen ve 12 aylık takip dönemini tamamlayan 119 hastanın verileri retrospektif olarak değerlendirildi. Çalışmada İGB uygulanan 20 hasta ve LSG yapılan 99 hasta yer aldı. Hastaların demografik verileri, yandaş hastalık, preoperatif ve postoperatif 12. ayda kilo ve VKİ verileri, verilen fazla kilo ve yüzdeleri, verilen fazla VKİ ve yüzdeleri kaydedilip gruplar karşılaştırıldı. Bulgular: LSG ve İGB grupları arasında preoperatif kilo açısından istatiksel anlamlı farklılık olduğu görüldü (sırasıyla 124,3 ± 17 ve 145,5 ± 24,7; p<0,001). Postoperatif 12. ayda ölçülen kilo değerlendirildiğinde İGB grubunda ortalama 119,2 ±28,5 kg ve LSG grubunda 78,9 ± 12,9 kg saptandı (p<0,001). İGB grubundaki hastaların 12.ay sonunda ortalama 26,3 ±12,8 kg kilo verdiği, LSG grubundaki hastalarında 45,35 ±12,2 kg kilo verdiği görüldü (p<0,001). Postoperatif 12. ayda saptanan verilen fazla kilo yüzdesi İGB grubunda 33,42 ±9,2%, LSG grubunda 67,68 ±14,9% saptandı (p‹0,001). Postoperatif 12.ayda saptanan verilen fazla VKİ yüzdesi açısından İGB grubunda 41 ±17,3%, LSG grubunda 81,48 ±18,8% saptandı (p<0,001). Sonuç: Morbid obes hastalarda endoskopik İGB uygulaması cerrahiye uygun olmayan veya cerrahi tedaviyi tercih etmeyen hastalarda etkin ve güvenli bir tedavi seçeneği olarak tercih edilebilir. Anahtar kelimeler: Morbid obezite, laparoskopik sleeve gastrektomi, intragastik balon

show abstract

“…Its use as a previous step prior to surgery is widely accepted, but it seems to be ineffective as a single method to reduce weight and its results are transient (1,2).…”

Section: Discussionmentioning

confidence: 99%

“…Although the intragastric balloon is relatively safe, there are significant risks and potential side effects derived from its insertion (2). Several reports have shown few severe but significant complications, sometimes in patients with a previous gastric surgical procedure (3,4) or with normal stomachs, occasionally related with its retrieval (5,6) or spontaneous perforation and subse- quent deflation (1), producing intestinal obstruction (7,8).…”

Section: Discussionmentioning

confidence: 99%

Gastric outlet obstruction after the insertion of a fully filled intragastric balloon

Redondo–Cerezo

Martos-Ruiz

Matas-Cobos

et al. 2013

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Analysis of Safety and Efficacy of Intragastric Balloon in Extremely Obese Patients

Abstract: Our study indicates the safety and efficacy of GBT in extremely obese patients particularly as a first step before a definitive anti-obesity operation. GBT appears to be a safe, tolerable, and potentially effective procedure for the initial treatment of morbid obesity.

Cited by 55 publications

References 27 publications

An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

An intragastric balloon in the treatment of obese individuals with metabolic syndrome: A randomized controlled study

Laparoscopic sleeve gastrectomy versus endoscopical intra-gastric balloon placement: early results of morbidly obese patients

Gastric outlet obstruction after the insertion of a fully filled intragastric balloon

Contact Info

Product

Resources

About